Compare NERV & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NERV | BANX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.1M | 191.0M |
| IPO Year | 2014 | 2013 |
| Metric | NERV | BANX |
|---|---|---|
| Price | $5.04 | $19.73 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 334.2K | 27.0K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,175,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $18.45 |
| 52 Week High | $12.46 | $23.67 |
| Indicator | NERV | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 56.24 |
| Support Level | $5.02 | $19.24 |
| Resistance Level | $5.61 | $19.95 |
| Average True Range (ATR) | 0.47 | 0.18 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 59.78 | 74.60 |
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.